Health Canada approves LYNPARZA™ (Olaparib) for the Treatment of Ovarian Cancer in Patients (BRCA-Mutations) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, May 04, 2016

Health Canada approves LYNPARZA™ (Olaparib) for the Treatment of Ovarian Cancer in Patients (BRCA-Mutations)



press release
 Health Canada approves LYNPARZA™ for the Treatment of Ovarian Cancer in Patients with BRCA-Mutations

MISSISSAUGA, ON, May 3, 2016 /CNW/ - AstraZeneca Canada announced today that Health Canada has approved LYNPARZA™ (olaparib) capsules as a maintenance treatment for patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer. LYNPARZA is the first poly ADP-ribose polymerase (PARP) inhibitor available in Canada, and has been granted the Health Canada Notice of Compliance with Conditions (NOC/c), based on promising evidence of clinical efficacy and duration of response data.1

"Health Canada's approval of LYNPARZA is particularly significant for patients with advanced BRCA-mutated ovarian cancer. Until now, there have been very limited options available to this unique segment of women living with this disease," says Dr. Michael Fung Kee Fung, Head, Division of Surgical Oncology, Ottawa Regional Cancer Centre and Professor, Division of Obstetrics & Gynecology and Department of Surgery, University of Ottawa. "The availability of this targeted treatment which works in the presence of BRCA mutations represents a successful application of our growing understanding of this disease. It gives us another way to battle this devastating disease, with fewer side effects compared to existing chemotherapies, which can often be debilitating for patients.".....


0 comments :

Post a Comment

Your comments?